Pricing

Intra-Cellular Therapies Inc (ITCI)

followers ยท
Sector: HEALTH CARE
Industry: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
CEO: Sharon Mates
Employees: 560
Web site: intracellulartherapies.com
135 ROUTE 202/206, SUITE 6, BEDMINSTER, NJ, 07921
(646) 440-9333
All 13F Filers Prior Change Hedge Funds 1 Prior Change
Intra-Cellular Therapies, Inc. develops novel drugs for the treatment of neuropsychiatric and neurologic diseases. The company offers CAPLYTA for schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for bipolar depression, as well as to treat auti® spectrum disorder.
Please log in first to see chart
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% Change in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available